Instructions for Ufalaza tablets blister No. 40
Composition
active ingredients: 1 tablet contains: affinity purified antibodies to endothelial NO synthase: a mixture of homeopathic dilutions C12, C30 and C200 - 6 mg; affinity purified antibodies to prostate-specific antigen: a mixture of homeopathic dilutions C12, C30 and C200 - 6 mg;
excipients: lactose monohydrate, microcrystalline cellulose, magnesium stearate.
Dosage form
Pills.
Main physicochemical properties: flat-cylindrical tablets with a bevel, white to almost white in color, with a score on one side.
Pharmacotherapeutic group
A complex homeopathic preparation.
Pharmacological properties
Pharmacodynamics.
It has been experimentally and clinically proven that affinity-purified antibodies to prostate-specific antigen (PSA) modify the functional activity of endogenous PSA, which is altered in benign prostatic hyperplasia, which is accompanied by an increase in the regulatory effect of this antigen on functional and metabolic processes in prostate tissue, and have a pronounced anti-inflammatory and anti-edema effect.
Affinity-purified antibodies to endothelial NO synthase contribute to an increase in blood flow velocity, including in the vessels of the penis and prostate gland; have a protective effect on the endothelium (contribute to a decrease in vascular reactivity, a decrease in vascular spasm and an improvement in peripheral microcirculation).
The combined use of components in the complex preparation "Ufalase" is accompanied by a synergistic effect: antibodies to endothelial NO synthase due to endothelioprotective action and improved vascularization enhance the antiproliferative and anti-inflammatory activity of antibodies to PSA. The synergistic effect is probably also due to nonspecific mechanisms of enhancing intracellular signal transduction by dilutions of antibodies to endothelial NO synthase.
In patients with benign prostatic hyperplasia (BPH), the drug, when used for 12 months, helps reduce prostate volume, improves urodynamics (reduced residual urine volume, increased maximum urine flow rate), and significantly reduces the severity of dysuric disorders without affecting PSA levels.
Pharmacokinetics.
The sensitivity of modern physicochemical analysis methods (gas-liquid chromatography, high-performance liquid chromatography, chromatography-mass spectrometry) does not allow assessing the content of active components of a medicinal product in biological fluids, organs and tissues, which makes it technically impossible to study pharmacokinetics.
Indication
Benign prostatic hyperplasia.
Dysuric disorders (as part of complex therapy): frequent urge to urinate, difficulty urinating, pain and discomfort in the perineum area, which accompany benign prostatic hyperplasia.
Contraindication
Increased individual sensitivity to the components of the drug.
Lactase deficiency, lactose intolerance, glucose-galactose malabsorption.
It is contraindicated for use in children (under 18 years of age).
Interaction with other medicinal products and other types of interactions
No cases of interaction with other drugs have been registered.
Application features
The medicinal product contains lactose monohydrate, therefore it should not be prescribed to patients with congenital galactosemia, glucose malabsorption syndrome or congenital lactase deficiency.
If the symptoms of the disease do not decrease or, on the contrary, increase, you should consult a doctor.
Use during pregnancy or breastfeeding.
For use in adult males. Do not use in women.
The ability to influence the reaction speed when driving vehicles or other mechanisms.
The drug does not affect the ability to drive vehicles and other potentially dangerous mechanisms.
Method of administration and doses
The drug is taken orally, 2 tablets per dose (do not take with food). Keep the tablet in your mouth (preferably without chewing or swallowing) until completely dissolved. Take the drug twice a day, in the evening and in the morning.
For dysuric disorders, it is recommended to take the drug for 16 weeks.
On the recommendation of a doctor, in case of severe pain syndrome and dysuric disorders, the drug is indicated to be taken up to 4 times a day in the first 2–3 weeks of therapy.
The duration of treatment is determined by the doctor individually.
To prevent prostate growth in patients with benign prostatic hyperplasia (BPH) and reduce the risk of disease progression, the drug is recommended to be taken twice a day, in the evening and in the morning, for 12 months.
Children
The drug is contraindicated in children (under 18 years of age).
Overdose
In case of accidental overdose, dyspeptic manifestations caused by the components included in the medicinal product are possible.
Side effects
Reactions of increased individual sensitivity to the components of the drug are possible.
Expiration date
3 years.
Do not use the medicine after the expiry date stated on the packaging.
Storage conditions
Store at a temperature not exceeding 25 °C.
Keep out of reach of children.
Packaging
20 tablets in a blister; 1 or 2 blisters in a cardboard box.
Vacation category
Without a prescription.
Producer
Santonica CJSC.
Address
Ukraine, 03062, Kyiv, Nyvska St., building 20,
Tel.: +380 (44) 400-90-78.
Applicant
LLC "Materia Medica-Ukraine".
